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INTRODUCTION
Chronic rhinosinusitis (CRS) is a common condition associat-
ed with significant morbidity and healthcare costs. In the USA 
alone, the prevalence is estimated at 14% of the population with 
significant economic consequences related to 73 million days 
off work. The annual medical cost is a staggering 2.4 billion US 
dollars.
1 Current therapeutic strategies remain inadequate. Thus 
there is an urgent unmet clinical need.
Rhinosinusitis is defined as inflammation of the nose and pa-
ranasal sinuses characterised by two or more symptoms, one of 
which should be nasal obstruction (blockage, congestion) or 
nasal discharge (anterior/posterior) along with either facial 
pressure/pain or reduction or loss of smell.
2 Confirmation of si-
nus-nasal mucosal inflammation via either endoscopic inspec-
tion or imaging is recommended to confirm the clinical diag-
nosis. Chronicity is arbitrarily defined by the persistence of 
symptoms beyond 12 weeks.
The evolutionary changes which led man to an upright stance 
have meant that sinus ventilation and drainage occur against 
gravity and are dependent upon patency of the slit-like ostiome-
atal complex area. Thus anything compromising this can act as 
a predisposing factor to rhinosinusitis.
CRS is not a distinct disease entity but an ‘umbrella’ term that 
groups together a spectrum of disorders with distinct immuno-
pathological mechanisms.
3 The exact pathogenesis remains 
poorly defined and treatments options are still limited and of-
ten ineffective. Currently, CRS is subclassified into two distinct 
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subtypes termed CRS without nasal polyps (CRSsNP) and CRS 
with nasal polyps (CRSwNP) (Figure). We will not discuss fun-
gal rhinosinusitis in this article. Whilst this sub-classification al-
lows clinicians to view two CRS groups with distinct yet related 
disease mechanisms separately, overall this classification re-
mains too simplistic. A significant proportion of patients still re-
main symptomatic despite maximal treatment. A therapeutic 
approach that incorporates defined clinical phenotypes with 
exact disease pathogenesis, an approach that is now more stan-
dard in allergic rhinitis is urgently needed.
4 
Immunopathology 
Chronic rhinosinusitis without nasal polyps (CRSsNP)
CRSsNP represents up to 60% of CRS cases and incorporates a 
heterogeneous group of disorders which can be distinct but yet 
can often sometimes overlap in aetiology and exacerbating fac-
tors. These include allergen driven IgE mediated inflammation, 
defects in both humoral and mucosal host-defence and nasal 
structural abnormalities. The overall immunopathogenesis is 
incompletely understood. Th1 dominance with a more signifi-
cant neutrophilic inflammation is seen, with an associated Th1 
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cytokine profile of IFN-γ, TNF-α, IL-1, IL-3, IL-6, and IL-8.
5,6 Im-
munoregulatory factors such as TGF-β1 is increased in expres-
sion and the key transcription factor implicated in Foxp
3+ T reg-
ulatory cell populations appear similar to the normal nasal mu-
cosa.
7 Why such severe immune dysregulation occurs, and 
what sustains inflammation is currently unknown, but it is like-
ly that there are additional immunological factors that may pro-
mote disease severity will emerge.
Tissue structural change (termed remodelling) is also present 
in CRSsNP with basement membrane thickening, excess goblet 
cell numbers, subepithelial glandular hyperplasia and hyper-
trophy, along with altered and excess extracellular matrix depo-
sition.
7 The exact mechanisms that lead to tissue remodelling 
remain unknown but one can speculate the mucosal injury-re-
pair cycle is poorly regulated and driven to excess as a result of 
the inflammatory burden. However, intrinsic defects in tissue 
repair mechanisms may still exist in CRS and contribute to re-
modelling. Whether such structural change promotes and sus-
tains the chronic inflammation in CRS is not known but very 
possible. It is also likely that remodelling contributes to disease 
severity in CRS with excess mucus production, tissue oedema 
with ostial obstruction and impaired mucociliary function. Ex-
trapolating from asthma studies current anti-inflammatory 
strategies are often ineffective in relation to neutrophilic inflam-
mation and have no definite effect on airway remodelling. 
Chronic rhinosinusitis with nasal polyps (CRSwNP)
CRSwNP is a more distinct immunological disease. Th2 dom-
inance with excess, IL-5, IL-4, and IL-13 expression is observed.
6 
IL-33 excess is associated with a recalcitrant CRS subtype.
8 Mu-
cosal eosinophilia is present in abundance.
6 Th17 cells are now 
also implicated, especially in Chinese polyps, with increased 
IL-17 expression related to eosinophil count and a more severe 
sino-nasal CT score.
9 FoxP3 expression is minimal suggesting a 
lack of T regulatory cell induced immunoregulation.
6 In addi-
tion there is a distinct local immune response to Staphylococ-
cus aureus enterotoxins (SAE) which act as superantigens, lead-
ing to polyclonal T cell and B cell activation, with excessive lo-
cal IgE production to not only SAE but other extrinsic and in-
trinsic allergens and cytokine secretion. However, CRSwNP 
from a Chinese cohort demonstrated excessive neutrophilic in-
flammation with skewing towards Th1/Th17 inflammation.
10 
Such findings highlight the complexity of unravelling the exact 
events that lead to disease and the current immaturity we have 
in our overall understanding of such processes. 
Eosinophils can lead to excessive tissue damage, but are now 
recognised as important in tissue repair but also remodelling.
11 
The observed denuded epithelium and epithelial shedding 
seen in CRSwNP is reminiscent of the ‘chronic wound scenario’ 
changes seen in asthmatic lower airways, where an activated 
epithelium can promote inflammation and sustain remodel-
ling by continued signalling to the underlying submucosal mes-
enchymal cells. The findings of defective epithelial barrier func-
tion in asthma have initiated an interest in the role of epitheli-
um in CRS where early reports of deficiency of epithelial pro-
teins implicated in barrier function and antimicrobial defence 
are emerging.
12 
Infection
The exact role of infection in the pathogenesis and mainte-
nance of CRS is currently under debate. Infection induced in-
flammation; bacterial superantigen-immune over-drive and 
infective osteitis have been considered as contributory in either 
distinct forms of CRS or as exacerbating factors in CRS with 
multifactorial aetiologies. In addition, there is recognition of 
defects in immunity, both innate and humoral. For example CF 
heterozygotes are over-represented in the CRS population.
13 
Even when immunoglobulin isotype levels are within the nor-
mal range, a high proportion of patients with recalcitrant CRSs-
NP fail to generate an adequate functional antibody response 
in response to unconjugated pneumococcal vaccination.
14 Low 
IgG3 levels have been reported in CRS patients compared to 
population controls.
15 Toll-like receptor (TLR)-2 is important 
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Figure.  Summary of therapeutic approaches to chronic rhinosinusitis. Chronic 
rhinosinusitis (CRS) can be broadly divided into CRS without nasal polyps 
(CRSsNP) and CRS with nasal polyps (CRSwNP). Further phenotyping of dis-
ease to identify exacerbating co-factors or distinct forms of disease such as im-
munodeficiency, aspirin sensitivity or vasculitis is needed, in to order to appro-
priately guide therapy. The approach with nasal douching, steroid therapy and 
antibiotics can often benefit most forms of CRS, but different subtypes are 
more responsive than others. Particularly individuals with aspirin sensitivity 
may benefit from leukotriene receptor inhibition and intranasal aspirin desensi-
tisation. Surgical correction of anatomical abnormalities that may predispose to 
exacerbation should be addressed. Kariyawasam et al.
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for mucosal recognition of gram-positive bacteria and initiation 
of mucosal defence. TLR-2 expression is lower in CRS popula-
tions and low TLR-2 relates to earlier disease relapse post-sur-
gery.
16 It is likely that there are other yet unknown defects in hu-
moral immunity in the sinonasal mucosa which may predis-
pose to infection and may even exaggerate mucosal immune 
leading to disease exacerbation or persistence.
17,18 However, the 
frequent lack of positive bacterial cultures from sinus cavities 
and variable and non-sustained response to antimicrobial ther-
apy has led to consideration of the role of bacterial biofilms in 
CRS. 
Bacterial biofilms 
Biofilm-forming bacteria include Haemophilus, Staphylococ-
cus and Pseudomonas species. A biofilm is considered an or-
ganised bacterial community that is characterised by adher-
ence to a mucosal (or foreign body) surface. The bacteria are 
embedded within an extensive polymeric substance termed a 
glycocalyx. The latter encases what is often a polymicrobial 
mixture of bacterial colonies and modulates the bacterial mi-
croenvironment, allowing interbacterial signalling (termed 
quorum sensing) and supports the development of bacterial 
virulence factors. The glycocalyx affords structural barrier pro-
tection and evasion by host-defence systems such as phagocy-
tosis and the complement system. Biofilm formation is con-
firmed in CRS
19 and there is growing evidence that biofilms 
may contribute to the relapse, persistence and severity of cer-
tain CRS subtypes.
20,21 Antibiotics can still penetrate biofilms, so 
the increased resistance to antimicrobial drugs is believed to be 
related to microbial community sharing of resistance genes and 
presence of slow bacterial growth conditions (thus slow metab-
olism).
22,23 It is presumed that persistence of infection will allow 
continued interaction and stimulation of the mucosal immune 
system, for example such as enterotoxin superantigens from S. 
aureus leading to polyclonal T cell activation and local hyper-
IgE production and activation of innate mucosal ‘danger-sens-
ing’ signals such the TLR system. The interaction of the biofilm 
itself in both biophysical and biochemical terms with mucosal 
tissue can theoretically at least contribute to disease pathogen-
esis and persistence. 
Therapeutic intervention 
Douching
A recent Cochrane meta-analysis shows that simply washing 
the nose with saline solutions is effective in CRS.
24 As yet the 
optimal formulation (normal/hypertonic) has not been deter-
mined.
Intranasal steroids
The ability of steroids to attenuate key aspects of the airway 
inflammatory response whilst supporting induction of impor-
tant immunoregulatory mechanisms, has established these 
compounds as first line therapy in treating CRS. Whilst disease 
in some groups of patients will respond to such therapy, there 
are significant proportion of patients for whom steroids are in-
effective. Thus it has become ever more important to define the 
exact phenotype of patients who are steroid sensitive, and study 
in detail the patient groups and the specific immune mecha-
nisms that occur in the steroid unresponsive groups. The failure 
to define exactly CRS subtypes has led to difficulty in interpret-
ing treatment response to therapy in several studies and as 
such, systematic review via meta-analysis has been limited. In 
fact the treatment response for steroid therapy in CRSsNP 
could not be defined via meta-analysis.
Chronic rhinosinusitis without nasal polyps (CRSsNP)
A systematic review of INS in CRSsNP in 2008 concluded that 
from published studies that incorporate all the strict criteria 
needed for analysis were applied, there were no articles that 
could be used to evaluate evidence for treatment response.
25 
This is disappointing and demands that well-designed studies 
are urgently needed. An early study in 1986 looked at the effect 
of Tixocortol Pivalate (a corticosteroid with topical anti-inflam-
matory activity equal to that of hydrocortisone) with neomycin 
or neomycin alone.
26 The study population was divided into in-
fective and allergic subtypes. The drug was administered via en-
dosinus irrigation once daily for 11 days. The study confirmed 
significantly less nasal obstructive symptoms with improved 
maxillary ostia patency in the group with both the steroid and 
antibiotic. What this study suggested was that INS effectively 
treats both types of CRS but concomitant treatment of infection 
if it is present leads to a significantly better treatment response. 
The duration of treatment, the lack of a placebo controlled arm 
to the study and inclusion of heterogeneous CRS patients such 
as those with nasal polyps weaken the data in terms of any defi-
nite conclusion.
As far as we are aware there are only 4 studies since then that 
have incorporated randomised design (evidence level Ib) and 
the insights gained are discussed below. A double blind place-
bo controlled randomised (DBPCR) study in CRS associated 
with associated chronic mucopurelence evaluated the effects 
dexamethasone-tramozoline (decongestant) with or without 
neomycin versus placebo propellant only, over 14 days.
27 Both 
treatment arms were clinically effective, and the presence of an 
antibiotic made no active difference. This data suggests that si-
nus drainage as a result of open sinus ostia is a key factor. Im-
proved mucociliary function (measured via the saccharin clear-
ance) improved in the treatment groups. The study is limited 
again in duration but also in that both atopic and non-atopic 
individuals were incorporated in the groups which limit num-
bers per CRS group and makes it difficult to say for which form 
of CRS such therapy is most effective. The authors state that 
treatment response was irrespective of IgE status. A DBPCR tri-
al of n=9 (active) and n=13 (placebo) completed therapy over Anti-Inflammatory and Antibiotic Approaches
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16 weeks failed to show any effect of the INS fluticasone propi-
onate 400 mcg per day, although two patients per group each 
had co-existent polyps.
28 The study was insufficiently powered 
to detect significant clinical response. 
In case treatment failure in CRS is related to poor delivery of 
INS into the sinus cavity, direct instillation of budesonide 256 
mcg daily into the maxillary antrum over 3 weeks has been un-
dertaken.
29 In this DBPCR approach, whilst the patient cohort 
here is stated as unresponsive to previous medical treatment 
with conventional regimes, direct sinus installation of drug was 
associated with prolonged clinical improvement alongside de-
creased mucosal Th2 inflammation. However all patients here 
had house-dust mite related perennial rhinitis associated CRS, 
and thus a distinct immune phenotype that is often steroid re-
sponsive. Inhaled budesonide is also effective in CRS
30 but 
again, whilst all patients fulfilled the clinical definition of CRS 
with persistent symptoms despite antibiotic therapy and nasal 
polyps were not present, 51% of patients were IgE positive to 
aeroallergens. Thus, again the exact CRS type that best re-
sponds to INS cannot be strictly confirmed from this otherwise 
well designed study. Fluticasone propionate (FP) is another 
topically active corticosteroid with established efficacy in sea-
sonal and perennial allergic rhinitis. A recent study evaluated 
FP 400 mcg BD delivered via a bi-directional flow breath-acti-
vated device (Optinose) that can deliver product more effec-
tively to the middle meatus. Whilst only n=10 patients were in 
the active arm, and again this population of CRSsNP with oth-
erwise difficult to treat was heterogeneous with both atopic and 
aspirin-sensitive individuals, significant clinical response was 
seen with treatment.
31 Further studies are urgently required, 
particularly in relation to homogenous CRSsNP populations 
before the exact therapeutic role of steroid therapy can be fully 
defined in this group. As far as we are aware there are no stud-
ies evaluating the role of systemic steroids in this group.
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Intranasal steroids 
The earliest study of intranasal steroids in moderate-severe 
nasal polyps evaluated beclomethasone dipropionate (BDP) 
400 mcg daily in n=35 patients randomised to treatment versus 
placebo.
32 After only 3 weeks there was a statistically significant 
improvement in nasal symptom scores. 
The EPO3S document included 15 studies on the basis of level 
Ib evidence for the intranasal treatment of CRSwNP, and only 
13 were considered of sufficient quality on the basis of strict 
definition of the patient group with CRSwNP, randomised dou-
ble-blind placebo controlled design and defined study out-
comes.
2 The higher number of studies in CRSwNP that fulfil the 
rigid criteria reflects the better-defined nature of the disease 
subtype. Within these studies however, there is still a mixed het-
erogeneity of disease with aspirin-sensitivity, the potential for 
eosinophil or neutrophil predominance and the role of local in-
fection and superantigen drive with local IgE production to 
consider. 
Recent meta-analysis on the basis of evaluating 6 studies
33-38 
confirms that INS are effective in CRSwNP.
25 Significant im-
provement in the polyp size score was seen in all six studies. 
The authors were unable to analyse the overall effect on nasal 
symptoms due to inconsistency in the methods used to score 
or record such changes. The authors excluded 7 studies because 
they could not ascertain the method of statistical analysis ful-
ly.
39-43 It is therefore useful to comment on individual highlight-
ed studies and identify important areas for further work. 
The most recent studies have been in relation to mometasone 
furoate and confirm that clinical response in CRSwNP is steroid 
dose related. Two related studies with mometasone furoate at 
200 mcg once daily over 16 weeks or once or twice daily over 16 
weeks compared to placebo give data on dose response of na-
sal polyps to MF. Once daily dosing was associated with signifi-
cant reductions in polyp size along with improved nasal ob-
struction, rhinorrhoea and sense of smell.
37,38 Twice daily dos-
ing when compared to once daily or placebo lead to greater im-
provement in nasal congestion, loss of smell and nasal discharge 
(anterior and posterior). Whilst these three studies were well 
designed and provide useful data, the failure to fully exclude in-
dividuals with perennial allergic rhinitis prevents the data relat-
ing solely to CRSwNP. 
In an early study comparing twice daily FP 200 mcg against 
BDP 200 mcg BD or placebo n=55 with mild polyps (score<3) 
over 26 weeks only BDP reached statistical significance in re-
duction in polyp score and improved symptoms.
41 However, 
both agents were clinically effective. FP group demonstrated an 
advantage over the BDP and placebo group on having signifi-
cant greater reduction in the need for rescue medication and 
less nasal blockage on morning awakening.
41 With patients list-
ed for surgical polypectomy and thus a more severe group, FP 
200 mcg BD group responded sooner with greater effect com-
pared to the BDP 200 mcg BD assigned patients.
44 Only the FP 
group reached statistical significance for decrease in total polyp 
score after 12 weeks of treatment. Active treatment here did not 
prevent the need for surgical intervention. This may suggest 
that spray forms of INS do not reach the middle meatus region 
effectively. Spray formulations are deposited mainly into the 
atrium of the nose. A droplet formulation can spread more ex-
tensively throughout the nasal cavity and it has been shown 
that three drops alone will cover most of the surface area of the 
nasal passage.
45 It has been shown that FP 400 mcg nasules di-
vided between each nostril taken daily
42,43 or twice-daily are 
both clinically effective, although the twice-day regime was 
seen to be more significantly effective.
42 In a second cohort of 
severe CRSwNP patients, administration of half-nasule con-
tents daily (alternate each nostril daily) over 12 weeks lead to 
significant decrease in polyp volume and improvement in as-
sociated symptoms of congestion, anterior and posterior nasal Kariyawasam et al.
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discharge and smell. Importantly, only 52% of patients pro-
ceeded to surgery.
46 
Both the aqueous and aerosol (powder) formulations of 
Budesonide (Bud) have been evaluated. Duration of studies 
has ranged from 4 weeks
39 to 8 weeks
35,36. In an early DBPCR 
study of n=19 (small polyps) over 4 months with a total of 400 
mcg of Bud as a pump spray in the active arm, changes in polyp 
size and number along with significantly improved nasal inspi-
ratory flow and symptom scores were confirmed.
47 This is a po-
tent steroid and other studies administering in powder form via 
a turbohaler device (800 mcg or 400 mcg daily, with no signifi-
cant dose-dependent difference in clinical effect ),
33,34 aqueous 
form 400 mcg daily
40 and 800 mcg daily
47 are clinically effective.
Systemic steroids 
The mechanical obstruction conferred by NPs may potential-
ly prevent the deposition of INS in the nasal mucosa and sinus 
cavity. In addition, the inflammatory burden maybe so intense 
in such patients that oral steroid has become first line therapy 
in such severe individuals. Systematic review
48 is again limited 
to only one study.
49 Here, oral prednisolone at 30 mg for 3 days 
and then 5 mg dose reduction every 2 days over 14 days in a se-
vere CRSwNP group significantly diminished polyp volume with 
less nasal obstruction and improved olfaction. These improve-
ments were then sustained with intranasal budesonide. In a 
separate study, high dose prednisolone at 50 mg for 14 days 
gave marked clinical improvement, highly correlated with the 
reduction in endoscopy and MRI scores of disease severity. 
Prednisolone did not confer any significantly greater adverse 
event compared to a placebo in severe CRSwNP.
50 
Leukotriene inhibitors
Chronic rhinosinusitis with/without nasal polyps
Open studies suggest that anti-leukotrienes might be of bene-
fit
51-53 Anti-leukotriene treatment in 36 patients with CRS with 
or without NP, added to standard treatment, resulted in statisti-
cally significant improvement in scores for headache, facial 
pain and pressure, ear discomfort, dental pain, purulent nasal-
discharge, postnasal drip, nasal congestion and obstruction, ol-
faction, and fever. Overall improvement was noted by 72% of 
the patients and side-effects occurred in 11%.
54 In 15 aspirin-
sensitive asthma triad patients, addition of an anti-leukotriene 
resulted in 9 with sinusitis experiencing improvement and 
over-all benefit in 12.
55 In 44 patients with nasal polyposis, sig-
nificant subjective improvement in nasal symptoms occurred 
in 64% aspirin tolerant and 50% aspirin sensitive patients. Sig-
nificant improvement in peak flow occurred only in the aspirin 
tolerant patients, while acoustic rhinometry, nasal inspiratory 
peak flow and nitric oxide levels were unchanged.
51 A prospec-
tive double blind comparative study on 40 patients compared 
the effects of the leukotriene receptor antagonist, monteleukast 
and beclomethasone nasal spray on the post-operative course 
of patients with sinonasal polyps. No significant differences were 
found in the year after surgery.
56 It is apparent that certain pa-
tients respond well to anti-leukotrienes, whilst others do not. 
The reasons for this are gradually becoming apparent
57 but at 
present pharmacogenetic testing is not easily available. Thus a 
simple therapeutic trial for one month with objective and sub-
jective monitoring is suggested, except in those patients where 
Churg Strauss syndrome is likely.
57
Aspirin desentisation 
Chronic rhinosinusitis without nasal polyps
There is no evidence.
Chronic rhinosinusitis with nasal polyps 
a) Aspirin tolerant
A DBPC trial of topical nasal lysine-aspirin plus FP spray 400 
mcg daily conferred no greater benefit than FP alone and re-
duced quality of life.
58 This suggest that the simple anti-inflam-
matory effect of aspirin is not indicated for all polyps. 
b) Aspirin intolerant (aspirin exacerbated respiratory disease)
Systemic aspirin desensitisation or topical lysine-aspirin treat-
ment may be effective.
Sixty-five aspirin-sensitive patients with nasal polyps and 
asthma underwent oral aspirin desensitization and subsequent 
daily aspirin treatment over 1 to 6 years (mean 3.1 years). There 
were significant reductions in sinus infections and an improve-
ment in olfaction. Numbers of sinus and polyp operations and 
doses of nasal corticosteroids per year were significantly reduced. 
There were also reductions in hospitalizations for treatment of 
asthma and use of systemic corticosteroids.
59-61
Nucera et al.
62 followed three groups of patients with nasal 
polyposis (half of whom were aspirin sensitive): the first 76 con-
secutive nasal polypectomy patients given topical nasal lysine 
aspirin afterwards, the second 49 patients with 40 mg triamcin-
olone retard (“medical polypectomy”) and subsequent nasal 
lysine aspirin and the third 191 control patients who underwent 
polypectomy but received no placebo. The group treated with 
lysine-acetylsalicylate postoperatively had a recurrence rate of 
6.9% after l year and 65% after six years post-operatively, while 
controls experienced recurrence in 51.3% at l year and 93.5% at 
six years, indicating significant protection against recurrence by 
lysine-aspirin. Systemic corticosteroid therapy and nasal lysine-
aspirin resulted in 33% with unchanged polyp size after three 
years compared to 15% in the operated-not treated group, but 
this was not statistically significant.
62 A case -controlled trial of 
treatment with lysine aspirin to one nostril and placebo to the 
other in 13 patients with bilateral nasal polyposis resulted in 
delayed polyp recurrence and 8 remained symptom free at 15 
months, significantly better than previous treatment with nasal 
steroid.
63
A small DBPCR trial in aspirin sensitive patients did not dem-Anti-Inflammatory and Antibiotic Approaches
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onstrate any effect on the nasal airway using 16 mg of intrana-
sal lysine aspirin every 48 hours after 6 months.
58 However im-
munohistochemistry revealed significant decrease of CyslLT 1 
receptor in the turbinate mucosa of the patients with active 
treatment, compared to placebo, so further trials were suggest-
ed (REF). Addition of nasal lysine aspirin (60 mg) to the routine 
regime of 13 previously poorly controlled nasal polyp patients 
reduced polyp size and did not adversely affect asthma.
64 Intra-
nasal lysine acetyl salicylate administration decreases polyp 
volume in patients with aspirin intolerant asthma.
64 An audit of 
our experience in over 100 patients gradually up-dosed to dos-
es ranging from 60 to 100 mg aspirin reveals benefit in the nasal 
airway and, after 12 months, in exhaled nitric oxide measures 
which in turn reflects sustained sinus ventilation, particularly 
in those with positive skin prick tests. Asthma outcomes were 
significantly better in 22 patients with aspirin exacerbated re-
spiratory disease who took lysine aspirin over 12 months com-
pared to 20 who were positive on challenge but either refused 
or rejected therapy because of side effects. These were mostly 
experienced during up-dosing and included local irritation, in-
creased nasal and sometimes asthma symptoms and occasion-
al gastric irritation (Scadding, manuscript in preparation). The 
mechanism of desensitisation probably involves reduction of 
leukotriene receptors and thus attenuation in cellular leukotri-
ene responsiveness.
65
Antibiotics 
The recognition of CRS as multifactorial in origin and not sim-
ply a persistent bacterial infection has lead to a re-evaluation of 
the role of antibiotics in treatment. It is appreciated that impaired 
sinus drainage can lead to secondary bacterial infection in all 
CRS forms, and patients benefit from antibiotic intervention for 
acute exacerbations of CRS. However, the role of antibiotics be-
yond this role is currently under debate. The use of antibiotics 
in CRS can be examined in terms of ‘short term’ and ‘long term’ 
use. However, the evidence base for such use is not clear cut, 
and has been hampered by clinical studies where the patient 
groups within CRS are again not clearly defined and often lack 
radiological confirmation of disease. In addition there are only 
a limited number of DBPCR trials evaluating such intervention. 
Short term treatment 
There is no clinical evidence that short term use of antibiotics 
have any effect in CRS. These findings must interpreted along-
side factors such as biofilm formation that may protect bacteria 
from antibiotic concentrations that lead to bacterial death on 
the culture plate having no effect in a biofilm niche. Further-
more, only a very limited number of studies exist and the study 
design is such that only limited interpretation is possible. The 
earliest study incorporated 15 patients with CRS (with no de-
tails of CRS subtype) randomised to either cefaclor or amoxicil-
lin with no placebo arm. After 10 days of treatment no clinical 
effect was seen in the CRS group.
66 There was no statistical eval-
uation. Legent et al.
67 evaluated the effect of ciproxin against 
amoxicillin/clavulanic acid over 9 days in an undefined hetero-
geneous population of CRS patients with mucopurulent dis-
charge. The other was an open randomised study with amoxi-
cillin/clavulanic acid against oral cefuroxime over 14 days.
68 
The lack of placebo arms in these studies diminishes the signif-
icance of the clinical response these may have had, and overall 
were negative studies in that they did not detect statistically sig-
nificant differences between the treatment arms. The remain-
ing studies are retrospective analysis of patient clinical outcomes 
in relation to 4 or 6 week antibiotic therapy,
69,70 and whilst re-
porting improvement in clinical parameters and of CT appear-
ance,
70 the studies lack methodological robustness to confer 
any definite conclusion. 
Long term treatment
Diffuse panbronchiolitis (DPB) is a disease seen mainly in 
Japanese populations and is rapidly fatal if untreated. It is char-
acterised by a progressive inflammatory obliteration of the 
small airways by lymphoid and scar tissue and is frequently as-
sociated with Pseudomonas aeruginosa co-infection. It is one of 
the sino-bronchial syndromes with a high incidence of CRS. 
The introduction of macrolides for DPB has reduced the mor-
tality of the disease from 90% to around 10%. The remarkable 
clinical efficacy of erythromycin in DPB, even when infecting 
microbial strains were antibiotic resistant, immediately suggest-
ed that macrolides have additional disease modifying features 
in the airway. Macrolides are clinically active as a result of their 
macrocyclic lactone ring. The potent immunosuppressant ta-
crolimus (FK506) and sirolimus are also macrolide compounds 
as a result of their macrocyclic lactone structure. Early reports 
since have suggested that both low dose erythromycin and clar-
ithromycin can benefit primary CRS
71 and these reports have 
been followed up with DBPCR studies evaluating the role of 
long term macrolides in CRS. The first randomised prospective 
study evaluated erythromycin over a 3 month period in CRS 
along with douching and INS, against just surgical intervention 
followed by INS with nasal douching in patients with persistent 
CRS.
72 Both the CRSsNP and CRSwNP groups demonstrated 
improvement in the visual analogue score similar to the surgi-
cal group at both 6 and 12 months of follow up. Only total nasal 
volume was greater in the surgery group. This study thus sug-
gests medical treatment for 3 months is indicated in both forms 
of CRS, and should be considered before surgery. A DBPCR tri-
al with roxithromycin over 3 months versus placebo in a more 
homogenous population of CRSsNP patients demonstrated 
significant improvement in olfaction, ciliary function, nasal flow 
and the SNOT-22 score of treatment.
73 Interestingly the group 
with low serum IgE in particular demonstrated a significant im-
provement in ciliary function, SNOT-22 along with decreased 
nasal lavage IL-8 levels. This is interesting as it suggests a partic-Kariyawasam et al.
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ular CRS-sub-phenotype will respond better to long term mac-
rolides therapy and provides a mechanistic insight into immu-
nopathogenesis. 
Erythromycin, clarithromycin and roxithromycin are all 
14-membered ring compounds and this structure may be rele-
vant as the 16-carbon ring macrolide josamycin has been inef-
fective in DPB.
74 Studies with the 15-membered ring structure 
compounds such as Azithromycin are awaited. The exact 
mechanism(s) as to how low-dose long term macrolides may 
confer treatment efficacy is still under debate. The macrolide 
mode of action is through the inhibition of bacterial protein 
biosynthesis. By reversibly binding to the bacterial ribosome 
50S subunit, inhibition of peptidyl-tRNA translocation occurs. 
Macrolides have a propensity to accumulate within leukocytes, 
and therefore are automatically translocated to sites of infection 
and inflammation.
75 The therapeutic effects of macrolides are 
not the simple result of the bactericidal effects of 50S ribosomal 
subunit suppression, as has been shown by the numerous stud-
ies in cystic fibrosis.
76 Conventionally gram negative bacteria 
such as pseudomonas are macrolide resistant. Thus effects on 
both immune modulation and attenuation of bacterial viru-
lence factors are considered important. The immunomodula-
tory role of macrolides is now evident with in-vivo confirmation 
on inhibiting neutrophil chemotaxis into tissue in response to 
LPS.
77 and neutrophil activation as evidenced by less free radi-
cal production.
78 Macrolides (14/15 member ring) directly sup-
press cytokine transcription via targeting factors NFκ-β and AP-
1,
79,80 and decrease levels of key neutrophil chemoattractant IL-
8, as well as IL-4, IL-5, and GM-CSF.
81 LTB4 (neutrophil che-
moattractant) production is inhibited by erythromycin at least 
in DPB.
82 
Microbial virulence is determined by both extracellular and 
cell-associated factors. Macrolides can directly inhibit such 
bacterial survival strategies. Clarithromycin can inhibit biofilm 
synthesis in P. aeruginosa in a dose-dependent manner again 
without any bactericidal activity against the bacterium.
83 Bio-
films facilitate “quorum-sensing” , allowing bacteria to effective-
ly coordinate the ‘on-off’ switch of such virulence genes through 
the production of auto-inducer molecules. Macrolides act as 
Pseudomonas quorum-sensing inhibitors.
Doxycycline is a member of the tetracycline antibiotic group 
and is commonly used to treat a variety of infections. Doxycy-
cline can also confer immunomodulation at sub-antimicrobial 
doses and has been used to treat airway diseases such sarcoid-
osis. Doxycycline is a potent inhibitor of matrix metalloproteas-
es.
84 A recent DBPC trial of doxycycline in CRSwNP over 20 days 
compared to methylprednisolone or placebo
85 provides some 
interesting data. As expected, the inflammatory biomarkers in 
nasal secretion IL-5 (Th2 cytokine essential for eosinophil re-
cruitment and survival), eosinophil cationic protein (ECP) and 
IgE were attenuated in the steroid arm, but interestingly myelo-
peroxidase and MMP-9 along with ECP decreased in the doxy-
cycline arm. Nasal polyp score decreased early on in the steroid 
group, whilst the moderate but significant decrease in relation 
to doxycycline was only evident just after 7 days of treatment 
and sustained up to 12 weeks post-treatment. Only a significant 
decrease in post-nasal drip was noted with doxycycline, whilst 
the steroid arm demonstrated significant improvement in con-
gestion, post-nasal drip and olfaction. Further studies are need-
ed. 
Topical antibiotics
The findings that serum antibiotic concentration of 1,000 
times the minimal inhibitory concentration (MIC) of moxiflox-
acin that can be achieved using oral therapy was required to in-
hibit an in-vitro model of S. aureus biofilm growth has led to 
consideration of topical antibiotic therapy directly to the sinus 
mucosa.
86 In a group of treatment resistant CRS cases with S. 
aureus culture positive disease, topical irrigation with mupiro-
cin 0.05% improved both symptom scores and endoscopic 
findings, only after 3 weeks of treatment. Nearly all the partici-
pants were culture negative after treatment.
87 In recalcitrant CRS 
this topical approach with mupirocin is undertaken. 
CONCLUSION
An understanding of the detailed immune-pathogenesis of 
the various forms of CRS is needed. This will allow molecular 
phenotyping into further several distinct mechanistic subtypes 
that will reveal specific therapeutic approaches. Until then, the 
current broad-based approach with general anti-inflammatory 
and anti-microbial strategies will continue. The use of nasal 
douching appears to be almost uniformly effective and should 
be the first line therapy.
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